DURECT (DRRX) Revenue & Revenue Breakdown
DURECT Revenue Highlights
Latest Revenue (Y)
$8.55M
Latest Revenue (Q)
$1.83M
Main Segment (Y)
Product
Main Geography (Y)
United States
DURECT Revenue by Period
DURECT Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $8.55M | -55.67% |
| 2022-12-31 | $19.28M | 37.96% |
| 2021-12-31 | $13.98M | -53.58% |
| 2020-12-31 | $30.11M | 1.85% |
| 2019-12-31 | $29.56M | 59.25% |
| 2018-12-31 | $18.56M | -62.25% |
| 2017-12-31 | $49.17M | 250.59% |
| 2016-12-31 | $14.03M | -26.66% |
| 2015-12-31 | $19.12M | -1.43% |
| 2014-12-31 | $19.40M | 26.59% |
| 2013-12-31 | $15.33M | -71.12% |
| 2012-12-31 | $53.07M | 58.48% |
| 2011-12-31 | $33.49M | 6.00% |
| 2010-12-31 | $31.59M | 30.04% |
| 2009-12-31 | $24.29M | -6.41% |
| 2008-12-31 | $25.96M | -15.38% |
| 2007-12-31 | $30.68M | 40.11% |
| 2006-12-31 | $21.89M | -23.37% |
| 2005-12-31 | $28.57M | 106.24% |
| 2004-12-31 | $13.85M | 17.05% |
| 2003-12-31 | $11.84M | 64.72% |
| 2002-12-31 | $7.18M | 10.13% |
| 2001-12-31 | $6.52M | 106.78% |
| 2000-12-31 | $3.15M | 3568.60% |
| 1999-12-31 | $86.00K | - |
DURECT generated $8.55M in revenue during NA 2023, up -55.67% compared to the previous quarter, and up 46.05% compared to the same period a year ago.
DURECT Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $1.83M | -31.55% |
| 2023-12-31 | $2.67M | 53.04% |
| 2023-09-30 | $1.74M | -16.19% |
| 2023-06-30 | $2.08M | 1.31% |
| 2023-03-31 | $2.05M | -38.04% |
| 2022-12-31 | $3.31M | -72.32% |
| 2022-09-30 | $11.98M | 476.93% |
| 2022-06-30 | $2.08M | 8.41% |
| 2022-03-31 | $1.92M | -73.76% |
| 2021-12-31 | $7.30M | 237.04% |
| 2021-09-30 | $2.17M | -5.99% |
| 2021-06-30 | $2.30M | 4.11% |
| 2021-03-31 | $2.21M | 0.23% |
| 2020-12-31 | $2.21M | -17.74% |
| 2020-09-30 | $2.68M | -89.62% |
| 2020-06-30 | $25.84M | 831.32% |
| 2020-03-31 | $2.77M | -74.03% |
| 2019-12-31 | $10.69M | -0.72% |
| 2019-09-30 | $10.76M | 170.09% |
| 2019-06-30 | $3.98M | -3.53% |
| 2019-03-31 | $4.13M | 13.90% |
| 2018-12-31 | $3.63M | -54.87% |
| 2018-09-30 | $8.04M | 135.45% |
| 2018-06-30 | $3.41M | -2.15% |
| 2018-03-31 | $3.49M | -82.15% |
| 2017-12-31 | $19.54M | -5.82% |
| 2017-09-30 | $20.75M | 380.34% |
| 2017-06-30 | $4.32M | -5.43% |
| 2017-03-31 | $4.57M | 29.85% |
| 2016-12-31 | $3.52M | -6.04% |
| 2016-09-30 | $3.74M | 18.56% |
| 2016-06-30 | $3.16M | -12.50% |
| 2016-03-31 | $3.61M | -30.17% |
| 2015-12-31 | $5.17M | 8.94% |
| 2015-09-30 | $4.74M | 6.80% |
| 2015-06-30 | $4.44M | -6.96% |
| 2015-03-31 | $4.77M | 11.81% |
| 2014-12-31 | $4.27M | 0.26% |
| 2014-09-30 | $4.26M | -7.05% |
| 2014-06-30 | $4.58M | -27.20% |
| 2014-03-31 | $6.29M | 46.72% |
| 2013-12-31 | $4.29M | 44.61% |
| 2013-09-30 | $2.97M | -24.30% |
| 2013-06-30 | $3.92M | -5.66% |
| 2013-03-31 | $4.15M | 27.31% |
| 2012-12-31 | $3.26M | -14.79% |
| 2012-09-30 | $3.83M | -20.18% |
| 2012-06-30 | $4.80M | -88.35% |
| 2012-03-31 | $41.19M | 360.94% |
| 2011-12-31 | $8.94M | 10.10% |
| 2011-09-30 | $8.12M | 3.60% |
| 2011-06-30 | $7.83M | -8.96% |
| 2011-03-31 | $8.60M | 1.27% |
| 2010-12-31 | $8.50M | 4.68% |
| 2010-09-30 | $8.12M | 10.98% |
| 2010-06-30 | $7.31M | -4.60% |
| 2010-03-31 | $7.67M | 57.15% |
| 2009-12-31 | $4.88M | -41.78% |
| 2009-09-30 | $8.38M | 71.79% |
| 2009-06-30 | $4.88M | -20.83% |
| 2009-03-31 | $6.16M | -20.27% |
| 2008-12-31 | $7.73M | 16.46% |
| 2008-09-30 | $6.63M | 5.25% |
| 2008-06-30 | $6.30M | -2.10% |
| 2008-03-31 | $6.44M | -2.23% |
| 2007-12-31 | $6.58M | - |
DURECT generated $1.83M in revenue during Q1 2024, up -31.55% compared to the previous quarter, and up 55.11% compared to the same period a year ago.
DURECT Revenue Breakdown
DURECT Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 20 | Dec 19 |
|---|---|---|---|---|
| Product | $6.27M | $6.08M | $6.17M | $11.44M |
| Collaborative Research And Development And Other Revenue | $2.28M | - | - | - |
DURECT's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (73.36%), and Collaborative Research And Development And Other Revenue (26.64%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative Research And Development And Other Revenue | $606.00K | $496.00K | $1.13M | $508.00K | $643.00K | $1.52M | $10.59M | $606.00K | $495.00K | $1.64M | - | - | - | - | - | - | - | - | - | - |
| Product | $1.56M | $1.33M | $3.29M | $1.57M | $1.41M | $1.80M | $1.39M | $1.47M | $1.42M | $2.72M | $1.72M | $1.57M | $1.64M | $2.38M | $2.50M | $2.81M | $3.44M | $3.02M | $2.35M | $2.63M |
DURECT's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (72.09%), and Collaborative Research And Development And Other Revenue (27.91%).
DURECT Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Other Foreign Countries | $1.07M | $557.00K | $642.00K | $657.00K | $2.13M |
| Europe | $2.30M | $11.79M | $6.63M | $1.39M | $3.13M |
| Japan | $559.00K | - | - | - | - |
| United States | $4.62M | - | - | - | - |
| JAPAN | - | $1.49M | $1.01M | $1.17M | $1.48M |
| UNITED STATES | - | $5.45M | $5.69M | $26.89M | $22.82M |
DURECT's latest annual revenue breakdown by geography, as of Dec 23: United States (54.01%), Europe (26.91%), Other Foreign Countries (12.54%), and Japan (6.54%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe | $644.00K | $543.00K | $1.26M | $613.00K | $431.00K | $606.00K | $10.43M | $414.00K | $338.00K | $5.75M | $297.00K | $282.00K | $301.00K | $-865.00K | $498.00K | $668.00K | $1.08M | $1.03M | $721.00K | $556.00K |
| JAPAN | $140.00K | $147.00K | $112.00K | $170.00K | $986.00K | $136.00K | $111.00K | $255.00K | $67.00K | $165.00K | $480.00K | $311.00K | $338.00K | $251.00K | $274.00K | $315.00K | $425.00K | $314.00K | - | - |
| UNITED STATES | $1.18M | $973.00K | $1.14M | $1.28M | $1.60M | $1.25M | $1.40M | $1.21M | $1.32M | $1.68M | $1.25M | $-73.00K | $1.35M | $24.50M | $1.11M | $8.49M | $8.98M | $2.86M | - | - |
| Other Foreign Countries | $205.00K | $164.00K | $684.00K | $213.00K | $175.00K | $127.00K | $162.00K | $153.00K | $115.00K | $164.00K | $123.00K | $172.00K | $183.00K | $-564.00K | $494.00K | $422.00K | $305.00K | $848.00K | $640.00K | $255.00K |
| J P | - | - | - | - | - | - | - | - | - | - | $303.00K | - | - | - | - | - | - | - | - | - |
| U S | - | - | - | - | - | - | - | - | - | - | $1.44M | - | - | - | - | - | - | - | - | - |
DURECT's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (54.44%), Europe (29.66%), Other Foreign Countries (9.44%), and JAPAN (6.45%).
DURECT Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| IRWD | Ironwood Pharmaceuticals | $442.74M | $94.40M |
| ORGO | Organogenesis | $433.14M | $130.23M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| ALIM | Alimera Sciences | $80.75M | $23.01M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| TKNO | Alpha Teknova | $36.68M | $9.61M |
| AVDL | Avadel Pharmaceuticals | $27.96M | $41.50M |
| AGRX | Agile Therapeutics | $19.59M | $5.58M |
| SNOA | Sonoma Pharmaceuticals | $12.73M | $3.44M |
| GHSI | Guardion Health Sciences | $12.25M | $36.35K |
| DRRX | DURECT | $8.55M | $1.83M |
| RDHL | RedHill Biopharma | $6.51M | $1.80M |
| EVOK | Evoke Pharma | $5.18M | $1.74M |
| ADMP | Adamis Pharmaceuticals | $4.76M | $9.06M |
| ACRX | Talphera | $651.00K | $117.00K |
| LSDI | Lucy Scientific Discovery | $7.05K | $9.68K |
| SHPH | Shuttle Pharmaceuticals | - | - |
DRRX Revenue FAQ
What is DURECT’s yearly revenue?
DURECT's yearly revenue for 2023 was $8.55M, representing a decrease of -55.67% compared to 2022. The company's yearly revenue for 2022 was $19.28M, representing an increase of 37.96% compared to 2021. DRRX's yearly revenue for 2021 was $13.98M, representing a decrease of -53.58% compared to 2020.
What is DURECT’s quarterly revenue?
DURECT's quarterly revenue for Q1 2024 was $1.83M, a -31.55% decrease from the previous quarter (Q4 2023), and a -11.05% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $2.67M, a 53.04% increase from the previous quarter (Q3 2023), and a -19.49% decrease year-over-year (Q4 2022). DRRX's quarterly revenue for Q3 2023 was $1.74M, a -16.19% decrease from the previous quarter (Q2 2023), and a -85.44% decrease year-over-year (Q3 2022).
What is DURECT’s revenue growth rate?
DURECT's revenue growth rate for the last 3 years (2021-2023) was -38.84%, and for the last 5 years (2019-2023) was -71.09%.
What are DURECT’s revenue streams?
DURECT's revenue streams in c 23 are Product, and Collaborative Research And Development And Other Revenue. Product generated $6.27M in revenue, accounting 73.36% of the company's total revenue, up 3.16% year-over-year. Collaborative Research And Development And Other Revenue generated $2.28M in revenue, accounting 26.64% of the company's total revenue
What is DURECT’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of DURECT was Product. This segment made a revenue of $6.27M, representing 73.36% of the company's total revenue.